Online Only Articles

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark
Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Sweden
Department of Oncology, Oslo University Hospital, Norway
Department of Oncology, Uppsala University Hospital, Sweden
Department of Hematology, Helsinki University Hospital, Finland
Department of Hematology, Rigshospitalet, Copenhagen, Denmark
Department of Hematology, Rigshospitalet, Copenhagen, Denmark
Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Sweden
Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2018.194399